|
Bill Flores
|
house |
abbott laboratories (aBT) |
ABT |
STOCK |
Purchase
|
June 10, 2014 |
$$15,001 - $50,000 |
July 10, 2014 |
|
Michael T. McCaul
|
house |
CORE LABS ARABYFIED RES INC |
CLAB |
STOCK |
Purchase
|
May 30, 2014 |
$$15,001-$50,000 |
June 10, 2014 |
|
Suzan K. DelBene
|
house |
ABB |
ABB |
STOCK |
P
|
May 12, 2014 |
$$15,001 - $50,000 |
June 12, 2014 |
|
John Hoeven
|
senate |
AbbVie Inc. (NYSE) |
ABBV |
STOCK |
Purchase
|
April 28, 2014 |
$$50,001 - $100,000 |
May 8, 2014 |
|
Pete Sessions
|
house |
abbvie Inc. (aBBV) |
ABBV |
STOCK |
Sale
|
April 23, 2014 |
$$1,001 - $15,000 |
May 14, 2015 |
|
Michael T. McCaul
|
house |
ARBOTT LABS INC |
ABT |
STOCK |
PURCHASE
|
April 14, 2014 |
$$50,001-$100,000 |
May 9, 2014 |
|
Katherine M. Clark
|
house |
abbVie Inc. (abbV) |
ABBV |
STOCK |
Sale
|
April 3, 2014 |
$$1,001 - $15,000 |
Dec. 19, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
April 2, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABRIV INCORPORATED (ABRV) |
ABRV |
STOCK |
PURCHASE
|
April 2, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
John Hoeven
|
senate |
AbbVie Inc. (NYSE) |
ABBV |
STOCK |
Purchase
|
March 31, 2014 |
$$50,001 - $100,000 |
April 23, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 24, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 21, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 21, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 21, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 21, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 21, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 20, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
James B. Renacci
|
house |
ABBVIE INCORPORATED (ABBV) |
ABBV |
STOCK |
PURCHASE
|
March 20, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
Michael T. McCaul
|
house |
AMBEST INC |
ABST |
STOCK |
Purchase
|
March 20, 2014 |
$$100,001-250,000 |
April 10, 2014 |
|
James B. Renacci
|
house |
ADVISORY BRD COMPANY (ABCD) |
ABCD |
STOCK |
PURCHASE
|
March 17, 2014 |
$$1,000 - $15,000 |
April 8, 2014 |
|
Bill Flores
|
house |
abbott laboratories (aBT) |
ABT |
STOCK |
P
|
Feb. 5, 2014 |
$$1,001 - $15,000 |
March 12, 2014 |
|
James B. Renacci
|
house |
ABBOTT LABS (ABT) |
ABT |
STOCK |
PURCHASE
|
Feb. 2, 2014 |
$$15,001 - $50,000 |
Jan. 27, 2014 |
|
Katherine M. Clark
|
house |
abbVie Inc. (abbV) |
ABBV |
STOCK |
Sale
|
Jan. 10, 2014 |
$$1,001 - $15,000 |
Dec. 19, 2014 |
|
Bill Flores
|
house |
Abbott Laboratories (ABT) |
ABT |
STOCK |
P
|
Dec. 30, 2013 |
$$15,001 - $50,000 |
Jan. 7, 2014 |
|
Michael T. McCaul
|
house |
ABERDEEN ESG EMERGING MKTS INST FD |
ABEMX |
FUND |
Purchase
|
Dec. 18, 2013 |
$$100,001-$250,000 |
Jan. 16, 2014 |